TSTickerStarGet alerts

SILO 10-Q filed 2026-11-13 | Key takeaways

SILO filed its 10-Q; the most relevant disclosure change is expanded Customer concentration: One customer accounted for 100% of license fee revenue in the nine months ended September 30, 2026; the mutual termination of the sublicense agreement with Aikido Pharma Inc. on September 2, 2026 resulted in zero revenue during Q3 2026 and recorded a $703,552. Customer concentration: Customer One (Aikido Pharma Inc.) represented 100% of revenue.

Share this story

Key takeaways

  • Revenue concentration: One customer accounted for 100% of license fee revenue in the nine months ended September 30, 2026; the sublicense termination resulted in zero Q3 2026 revenue.

  • Net loss narrowed: Q3 2026 loss of $358,743 improved from $1,110,438 in Q3 2025; nine-month loss of $2,838,689 compared favorably to $3,346,168 in the prior-year period.

  • Capital raise completed: July 2026 private placement raised $4.0 million gross ($3.48 million net) through common stock, pre-funded warrants, and Series A-3/A-4 warrants; November 2026 private placement raised approximately $815,000 net.

  • Stock repurchase active: Board authorized $1.0 million repurchase plan on February 20, 2026; 20,543 shares held in treasury at September 30, 2026 with cost basis of $44,775.

  • Authorized shares expanded: Shareholders approved increasing authorized common stock from 6,666,667 to 250,000,000 shares on August 14, 2026, following a 1-for-15 reverse stock split effective June 2, 2026.

  • Subsidiary formed: Kloneintel LLC (70%-owned) formed on November 3, 2026 to operate KLONE software assets acquired from Norsight Consulting Inc. for a warrant to purchase 300,000 shares valued at $381,242.

  • Asset purchases recorded: Three software asset purchases during 2026—Many Ads ($714,000 for qwikagents.com assets), Parkview ($506,550 for reputation endpoints software), and Norsight ($381,242 warrant for KLONE platform)—all expensed as R&D with no alternative future use.

Key metrics

Net loss - Q3Q3 2026
$358,743$751,695 improvement from Q3 2025 loss of $1,110,438
Net loss - Nine monthsNine months ended September 30, 2026
$2,838,689$507,479 improvement from nine months ended September 30, 2025 loss of $3,346,168
License fee revenue - Q3Q3 2026
$0Declined from $18,025 in Q3 2025 due to sublicense termination
License fee revenue - Nine monthsNine months ended September 30, 2026
$18,026Declined from $54,076 in nine months ended September 30, 2025
Net loss per common share - basic and diluted Q3Q3 2026
$0.21Improved from $1.79 per share in Q3 2025
Net loss per common share - basic and diluted nine monthsNine months ended September 30, 2026
$2.26Improved from $7.47 per share in nine months ended September 30, 2025
Cash used in operations - Nine monthsNine months ended September 30, 2026
$2,208,018Improved from $3,881,061 used in nine months ended September 30, 2025
Cash and cash equivalentsSeptember 30, 2026
$6,088,184Increased from $3,917,627 at September 30, 2025

Customer concentration

Customer One (Aikido Pharma Inc.)Nine months ended September 30, 2026
100%Share of revenue

Disclosure changes

  • Customer concentration

    One customer accounted for 100% of license fee revenue in the nine months ended September 30, 2026; the mutual termination of the sublicense agreement with Aikido Pharma Inc. on September 2, 2026 resulted in zero revenue during Q3 2026 and recorded a $703,552 gain on termination in other income.

    Complete loss of the company's single revenue-generating customer relationship; the gain on termination partially offsets the operational loss but represents a non-recurring item.
  • Subsequent events - Kloneintel formation

    On November 3, 2026, the company formed Kloneintel LLC (70%-owned subsidiary) to operate KLONE software assets purchased from Norsight Consulting Inc. on October 1, 2026; Kloneintel is a purpose-built SaaS platform that centralizes performance feedback.

    New subsidiary formed to commercialize acquired KLONE software; 70% ownership indicates retained economic interest; represents company expansion into SaaS performance feedback market.
  • Subsequent events - November 2026 Private Placement

    On November 6, 2026, the company closed a private placement yielding approximately $815,000 in net proceeds after deducting placement agent fees and offering expenses.

    Additional capital raise completed after quarter-end; combined with July 2026 proceeds, total Q3/Q4 2026 gross proceeds of approximately $5 million strengthens balance sheet.
  • Stockholders' equity - Authorized shares increase

    On August 14, 2026, shareholders approved increasing authorized common stock from 6,666,667 to 250,000,000 shares; common stock par value $0.0001; 1,907,560 shares issued and 1,887,017 shares outstanding at September 30, 2026.

    Significant increase in authorized shares provides flexibility for future equity offerings; dilution potential increased substantially.
  • Treasury stock

    20,543 shares of treasury stock held at September 30, 2026 with cost basis of $44,775; 6,015 shares repurchased and cancelled on August 5, 2026; additional 20,543 shares repurchased during August-September 2026.

    Company actively repurchasing shares under $1 million authorized program; reduces shares outstanding and partially offsets dilution from warrant exercises.
  • Asset purchases - Parkview Agreement

    On August 18, 2026, company issued 165,000 shares of common stock (valued at $506,550 or $3.07 per share) to Parkview Consulting LLC for Reputation Endpoints software and related intellectual property; entire consideration expensed as R&D with no alternative future use; shares subject to 12-month lock-up.

    Third software asset acquisition in 2026; all three expensed as R&D due to lack of alternative future use; reflects company strategy to build AI and software capabilities through asset acquisitions.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow SILO in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert